Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Exploratory Analyses of Lymph Node Tissue, Serum, and Peripheral Blood Mononuclear Cells Do Not Reveal Pathogen Signatures in Idiopathic Multicentric Castleman Disease

Ira Miller, Daniel Jose Arenas, Melanie Mumau, Michael V. Gonzalez, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 4402.

https://doi.org/10.1182/blood-2023-188991

Published: 2023

Journal Articles

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Kayleen Ports, Rahul Jain, Sheila Diamond, Jacob Aptekar, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 6933.

https://doi.org/10.1182/blood-2023-181968

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Trends, and Outcomes of Patients with HHV-8-Negative/Idiopathic Multicentric Castleman Disease Treated with Siltuximab in a Machine Learning-Selected Real-World Cohort

Aaron B Cohen, Melissa Estevez, Jonathan G Kelly, James N Gippetti, Erin L Fidyk, Joshua D. Brandstadter, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 907.

https://doi.org/10.1182/blood-2023-174924

Published: 2023

Journal Articles

Clinical Characteristics and Treatment Outcomes of Idiopathic Multicentric Castleman Disease: Data from a Pediatric Cohort

Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Sheila K. Pierson, Joshua D. Brandstadter, Frits van Rhee, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2023-183039

Published: 2023

Journal Articles

A Translational Approach to Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman Disease

Melanie Mumau, Abiola Irvine, Chunyu Ma, Sheila K. Pierson, Brent Shaw, Michael V. Gonzalez, Daniel Korn, Tracey Sikora, Grant Mitchell, David Koslicki, Luke Y. C. Chen, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2023-188076

Published: 2023

Journal Articles

The Role of CABIN1 in the Pathogenesis of Idiopathic Multicentric Castleman Disease

Dorottya Laczko, David C. Fajgenbaum, Taku Kambayashi

Blood (2023) 142 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2023-182283

Published: 2023

Journal Articles

Identification of Autoantibodies Associated with Connective Tissue Disorders in Idiopathic Multicentric Castleman Disease

Allan Feng, Michael V. Gonzalez, Melanie Mumau, Saishravan Shyamsundar, Paul J. Utz, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2023-189788

Published: 2023

Journal Articles

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, Daisy Alapat, Adam Bagg, Joshua D Brandstadter, Mary Jo Lechowicz, Hongzhe Lee, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 6520–6521.

https://doi.org/10.1182/blood-2022-170102

Published: 2022

Journal Articles

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Sheila K Pierson, Mateo Sarmiento Bustamante, Joshua D Brandstadter, Daisy Alapat, Adam Bagg, Mary Jo Lechowicz, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 9378–9379.

https://doi.org/10.1182/blood-2022-170360

Published: 2022

Journal Articles

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Vibhu Agarwal, Jacob Aptekar, David C Fajgenbaum, Penelope Lafeuille

Blood (2022) 140 (Supplement 1): 7838–7839.

https://doi.org/10.1182/blood-2022-169287

Published: 2022

Journal Articles

Serum Proteomics Identifies Interferon Gamma Signaling in Idiopathic Multicentric Castleman Disease

Melanie Mumau, Sheila K Pierson, Michael Gonzalez, Scott Canna, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 5500–5501.

https://doi.org/10.1182/blood-2022-167829

Published: 2022

Journal Articles

A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders

Joshua D Brandstadter, Angelina De Martin, Mechthild Lϋetge, Antonio Ferreira, Brian T. Gaudette, Michael Gonzalez, Yves Stanossek, Edward Camiolo, Gerald Wertheim, David Allman, David C Fajgenbaum, Jon C. Aster, Burkhard Ludewig, Ivan Maillard

Blood (2022) 140 (Supplement 1): 3562–3563.

https://doi.org/10.1182/blood-2022-159835

Published: 2022

Journal Articles

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Adi Zoref-Lorenz, David C. Fajgenbaum, Sheila K. Pierson, Abiola Oladapo, John Yee, Nitya Gulati, Carl E. Allen, Michael B. Jordan

Blood (2022) 140 (Supplement 1): 11170–11171.

https://doi.org/10.1182/blood-2022-170288

Published: 2022

Journal Articles

Red Blood Cell Morphological Changes and Enlarged Platelets Found in Idiopathic Multicentric Castleman Disease

Ayelet I Rubenstein, Sheila K Pierson, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2021-146568

Published: 2021

Journal Articles

Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease

Sheila K Pierson, Russell Perkins, Frits van Rhee, Corey Casper, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 2696.

https://doi.org/10.1182/blood-2021-153797

Published: 2021

Journal Articles

Characterizing Serum Cytokine Levels in Idiopathic Multicentric Castleman Disease Reveals Increased Chemokines and a Potential Signature Compared to Related Diseases

Sheila K Pierson, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 2693.

https://doi.org/10.1182/blood-2021-153893

Published: 2021

Journal Articles

Ongoing Symptoms and Reduced Health Measures in Unicentric Castleman Disease Patients Despite Perceived-to-be Curative Surgical Excision

Freda R Coren, Mateo Sarmiento Bustamante, Sheila K Pierson, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2021-153756

Published: 2021

Journal Articles

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity

Jean-Francois Rossi, Hao-Chun Chiang, Zhao-Yang Lu, Kalle Levon, Frits van Rhee, Karan Kanhai, David C Fajgenbaum, Bernard Klein

Blood (2021) 138 (Supplement 1): 4004.

https://doi.org/10.1182/blood-2021-150433

Published: 2021

Journal Articles

Increased mTORC2 Pathway Activation in Lymph Nodes of Imcd-Tafro

Alexis D Phillips, Joseph K Kakkis, Patricia Y Tsao, Sheila K Pierson, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2021-146821

Published: 2021

Journal Articles

Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease

Sheila K Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S. Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S. Uldrick, Frits van Rhee, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 1623.

https://doi.org/10.1182/blood-2021-153397

Published: 2021

NARROW

Exploratory Analyses of Lymph Node Tissue, Serum, and Peripheral Blood Mononuclear Cells Do Not Reveal Pathogen Signatures in Idiopathic Multicentric Castleman Disease

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Clinical Characteristics, Treatment Trends, and Outcomes of Patients with HHV-8-Negative/Idiopathic Multicentric Castleman Disease Treated with Siltuximab in a Machine Learning-Selected Real-World Cohort

Clinical Characteristics and Treatment Outcomes of Idiopathic Multicentric Castleman Disease: Data from a Pediatric Cohort

A Translational Approach to Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman Disease

The Role of CABIN1 in the Pathogenesis of Idiopathic Multicentric Castleman Disease

Identification of Autoantibodies Associated with Connective Tissue Disorders in Idiopathic Multicentric Castleman Disease

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Serum Proteomics Identifies Interferon Gamma Signaling in Idiopathic Multicentric Castleman Disease

A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Red Blood Cell Morphological Changes and Enlarged Platelets Found in Idiopathic Multicentric Castleman Disease

Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease

Characterizing Serum Cytokine Levels in Idiopathic Multicentric Castleman Disease Reveals Increased Chemokines and a Potential Signature Compared to Related Diseases

Ongoing Symptoms and Reduced Health Measures in Unicentric Castleman Disease Patients Despite Perceived-to-be Curative Surgical Excision

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity

Increased mTORC2 Pathway Activation in Lymph Nodes of Imcd-Tafro

Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only